No Data
No Data
Zhejiang Medicine Co., Ltd. (SHSE:600216) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Zhejiang Medicine Co., Ltd. (SHSE:600216) shares have continued their recent momentum with a 28% gain in the last month alone. Looking further back, the 14% rise over the last twelve months isn't
Zhejiang Medicine (600216.SH): The life nutrition sector includes vitamin D3.
Zhejiang Medicine (600216.SH) stated on the investor interaction platform on July 19 that its life nutrition sector includes vitamin D3, but the product's production and sales volume accounts for an insignificant proportion of the company's overall revenue and the overall market demand for the product. Therefore, the company expects that changes in the market quote for this product will not have a significant impact on its performance.
Zhejiang Medicine Co., Ltd.'s (SHSE:600216) Stock Is Going Strong: Have Financials A Role To Play?
Zhejiang Medicine (SHSE:600216) has had a great run on the share market with its stock up by a significant 26% over the last three months. Given that stock prices are usually aligned with a company'
Zhejiang Medicine (600216.SH) will distribute equity for the year 2023: 0.15 yuan per share.
Zhejiang Medicine (600216.SH) announced the implementation of equity distribution for the year 2023: before the implementation of the plan...
Individual Investors in Zhejiang Medicine Co., Ltd. (SHSE:600216) Are Its Biggest Bettors, and Their Bets Paid off as Stock Gained 5.9% Last Week
Key Insights Significant control over Zhejiang Medicine by individual investors implies that the general public has more power to influence management and governance-related decisions The top 25 sha
China Grants Clinical Trial Approval for Zhejiang Medicine's Antibacterial Injection
China's medical products administrator granted clinical trial approval to Zhejiang Medicine's (SHA:600216) LYSC98 injectable antibacterial drug indicated for common clinical gram-positive bacteria, ac
No Data